Dova Pharmaceuticals Financials

$642.8 M

Mkt cap, 31-Oct-2017
Net income (FY, 2016)(27.2 M)
EBIT (FY, 2016)(27 M)
Closing share price, 2017-10-3125.3
Cash, 31-Dec-201628.7 M
EV627.8 M

Revenue/Financials

Income Statement

Annual

USDFY, 2016

R&D expense

25.8 m

General and administrative expense

1.2 m

Operating expense total

27 m

EBIT

(27 m)

Income tax expense

152 k

Net Income

(27.2 m)

Balance Sheet

Annual

USDFY, 2016

Cash

28.7 m

Current Assets

28.7 m

Total Assets

28.7 m

Accounts Payable

157 k

Current Liabilities

8.3 m

Long-term debt

13.6 m

Total Debt

13.6 m

Total Liabilities

22 m

Common Stock

17 k

Preferred Stock

1 k

Additional Paid-in Capital

34 m

Retained Earnings

(27.2 m)

Total Equity

6.8 m

Debt to Equity Ratio

2 x

Debt to Assets Ratio

0.5 x

Financial Leverage

4.2 x

Cash Flow

Annual

USDFY, 2016

Net Income

(27.2 m)

Accounts Payable

157 k

Cash From Operating Activities

(987 k)

Cash From Financing Activities

29.7 m

Interest Paid

3 k

Ratios

USDY, 2016

EV/EBIT

-23.2 x

EV/CFO

-636 x

Debt/Equity

2 x

Debt/Assets

0.5 x

Financial Leverage

4.2 x
Report incorrect company information

Operating Metrics

Mar, 2017Jun, 2017

Patents (foreign)

24

Patents Licensed

43

Patents Pending (foreign)

2

Phase III Trials Products

1
Report incorrect company information